Judges: Dyk (author), Bryson, and Linn In Andrx Pharmaceuticals, Inc. v. Biovail Corp., No. 01-1650 (Fed. Cir. Jan. 17, 2002), the Federal Circuit vacated and remanded a lower court’s order (1) shortening the statutory thirty-month delay of FDA approval of Andrx Pharmaceuticals, Inc.’s (“Andrx”) Abbreviated New Drug Application (“ANDA”), and (2) ordering that the FDA approve the ANDA. Under the Hatch-Waxman Amendments, a pioneer drug manufacturer having an approved New Drug Application (“NDA”) must notify the FDA of all patents claiming the drug covered by the NDA. The FDA lists these patents in the “Orange Book.” A generic drug manufacturer can submit an ANDA, as opposed to a full NDA, if the manufacturer can show the generic drug’s bioequivalence with an FDA-approved
The US Federal Circuit Court finds that the district court exceeded its authority in shortening the statutory stay of entry by a generic competitor which was challenged by a pharmaceutical patent-holder manufacturer in a patent infringement suit (Andrx / Biovail)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.